Medication Profile of Patients in the University of Puerto Rico Inflammatory Bowel Disease Registry

Melendez, Jorge; Larregui, Yaritza; Vázquez, J. Romero; Carlo, Victor; Torres, Esther

doi:10.14309/00000434-200809001-01136

Cited by 6 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 16 , 24 Colectomy rates varied between countries, with 22% of patients in Puerto Rico, 10.5% in Montevideo, Uruguay, 10.1% in Mexico City and 1.5–3.4% in Bahia, Brazil requiring a colectomy. 16 , 17 , 29 , 34 , 36 In Montevideo, Uruguay, 5.0% of patients underwent proctocolectomy (3.8% pouch and 1.3% definitive ileostomy) and 4.2% of patients required a colectomy. 36 …”

Section: Resultsmentioning

confidence: 99%

“…A total of 10 studies reported treatment use by patients with UC in Latin America (Table 5). Generally, a low proportion of patients were treated with biologics, ranging from 0.8% in Puerto Rico to 16.2% in Mexico, 30,34 with the exception of Mato Grosso do Sul, Brazil, in which 44.4% of patients received tumour necrosis factor inhibitors (TNFi; 35.0% received adalimumab and 19.7% received infliximab). 19 The proportions of patients treated with 5-aminosalicylates, corticosteroids or immunosuppressants varied between studies, but were generally higher than the proportions of patients treated with biologics.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Review of the epidemiology and burden of ulcerative colitis in Latin America

Kotze

Steinwurz

Francisconi

et al. 2020

Therap Adv Gastroenterol

View full text Add to dashboard Cite

The incidence and prevalence of ulcerative colitis (UC) has been reported to be rising in newly industrialised regions, such as Latin America. Here, we review data from published studies reporting demographics and clinical aspects of UC in Latin America to further understand epidemiology and disease burden. The incidence and prevalence of UC in Latin America varied between regions and studies, ranging between 0.04 to 8.00/100,000 and 0.23 to 76.1/100,000, respectively, and generally increased over the period from 1986 to 2015. The majority of patients with UC were female (53.6–72.6%) and urban residents (77.8–97.4%). Extraintestinal manifestations were reported in approximately 26–89.4% of patients. Use of biologic therapies was generally low (0.8–16.2%), with the exception of Mato Grosso do Sul, Brazil, with a greater proportion of patients tending to receive 5-aminosalicylates, immunosuppressants or corticosteroids; colectomy rates varied between studies (1.5–22%). A high proportion of patients had moderate to severe UC (45.9–73.0%) and, in 11 of 19 studies, the greatest proportion of patients had extensive disease (pancolitis). Colorectal cancer (0–1.7%) and mortality rates (0–7.6%) were low. This evaluation of published studies may influence therapeutic approaches and the development of strategies to improve healthcare access and patient outcomes, although further high-quality studies are required in patients with UC in Latin America.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Review of the epidemiology and burden of ulcerative colitis in Latin America

Kotze

Steinwurz

Francisconi

et al. 2020

Therap Adv Gastroenterol

View full text Add to dashboard Cite

show abstract

“…[50]One study found a higher prevalence of left-sided colitis, higher mortality, and higher usage of biological agents in Mexican population than in Mexican-American population, supporting the role of environmental factors on clinical characteristics of IBD. [24] The larger case-series in LAC Countries are from 1946 to date are from Argentina [14,51,52], Barbados [13], Brazil [14,[53][54][55][56][57][58][59][60][61][62][63][64][65], Chile [66][67][68], Cuba [69], Peru [70,71], Puerto Rico [72][73][74][75] and Uruguay. [76][77][78] Most CD localizations were ileal-colonic and CD behavior was mostly inflammatory, followed by penetrant or stenotic.…”

Section: Discussionmentioning

confidence: 99%

Epidemiology of inflammatory bowel disease in Mexico and Colombia: Analysis of health databases, mathematical modelling and a case-series study

et al. 2020

View full text Add to dashboard Cite

Background and aims Ulcerative Colitis (UC) and Crohn's Disease (CD) have a major impact on quality of life and medical costs. The aim of the study was to estimate the prevalence, incidence and clinical phenotypes of Inflammatory Bowel Disease (IBD) cases in Mexico and Colombia. Methods We analyzed official administrative and health databases, used mathematical modelling to estimate the incidence and complete prevalence, and performed a case-series of IBD patients at a referral center both in Mexico and Colombia. Results The age-adjusted complete prevalence of UC per 100,000 inhabitants for 2015/2016 ranged from 15.65 to 71.19 in Mexico and from 27.40 to 69.97 in Colombia depending on the model considered. The prevalence of CD per 100,000 inhabitants in Mexico ranged from 15.45 to 18.08 and from 16.75 to 18.43 in Colombia. In Mexico, the age-adjusted incidence of UC per 100,000 inhabitants per year ranged from 0.90 to 2.30, and from 0.55 to 2.33 in Colombia. The incidence for CD in Mexico ranged from 0.35 to 0.66 whereas in Colombia, the age-adjusted incidence of CD ranged from 0.30 to 0.57. The case-series included 200 IBD patients from Mexico and 204 patients from Colombia.

show abstract

“…Disease duration at the time of inclusion in the Registry was calculated from the time of symptom onset and from the time of diagnosis. Medications used have been reported in a separate study [ 20 ]. Summary measures were used to describe the study group.…”

Section: Methodsmentioning

confidence: 99%

Inflammatory Bowel Disease in Hispanics: The University of Puerto Rico IBD Registry

Torres

Cruz

Monagas

et al. 2012

International Journal of Inflammation

View full text Add to dashboard Cite

A registry of patients with inflammatory bowel diseases, ulcerative colitis (UC) and Crohn's disease (CD), was created at the University of Puerto Rico in 1995. Subjects with a documented diagnosis of IBD by clinical, radiologic, endoscopic, and/or pathologic criteria were recruited from the IBD clinics, support groups, and community practices, and demographic and medical data was collected. All entries from 1995 to 2009 were analyzed for demographics, family history, disease extent, extraintestinal manifestations, surgery, and smoking history. Results were described using summary statistics. 635 Hispanics living in Puerto Rico, 299 with UC and 336 with CD, were included. Mean ages were 40.3 for UC and 30.9 for CD. Over half (56%) of UC and 41% of CD were females. Family history was present in 19.3% of UC and 17.5% of CD. Surgery for IBD had been performed in 31.9% of UC and 51.2% of the CD patients. Over one-fourth of the patients reported extraintestinal manifestations, most frequently arthropathies. Our findings contribute to the limited epidemiologic and clinical data on Hispanics with IBD.

show abstract

Medication Profile of Patients in the University of Puerto Rico Inflammatory Bowel Disease Registry

Cited by 6 publications

References 0 publications

Review of the epidemiology and burden of ulcerative colitis in Latin America

Review of the epidemiology and burden of ulcerative colitis in Latin America

Epidemiology of inflammatory bowel disease in Mexico and Colombia: Analysis of health databases, mathematical modelling and a case-series study

Inflammatory Bowel Disease in Hispanics: The University of Puerto Rico IBD Registry

Contact Info

Product

Resources

About